Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-22-001419
Filing Date
2022-02-11
Accepted
2022-02-11 16:54:08
Documents
1
Period of Report
2022-02-09

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 9806
  Complete submission text file 0001562180-22-001419.txt   11363
Mailing Address ONE PENN PLAZA, 19TH FLOOR NEW YORK NY 10119
Business Address
GUYER DAVID R (Reporting) CIK: 0001277476 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51122 | Film No.: 22622202

Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Issuer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 3826 Laboratory Analytical Instruments